RT Journal Article
T1 Standardization of canine infections for the development of antileishmanial drugs
A1 Olías-Molero, A. I.
A1 Corral-Caridad, M. J.
A1 Jiménez-Antón, M. D.
A1 Mateo Barrientos, Marta
A1 Carrión, J.
A1 Torrado Durán, Juan José
A1 Alunda Rodríguez, José María
AB Chemotherapy of leishmaniasis, both human and canine, is far from ideal and new antileishmanial drugs are urgently needed. Therapeutic arsenal against the disease is old, of low antileishmanial efficacy and hampered by toxicity issues in some cases. Furthermore, hospitalization required for some drugs, the price of the safer presentations is high and there are growing reports of leishmanial resistance to first line medicines. In addition to human visceral cases, canine infections by Leishmania infantum represent a first order veterinary pathology with dogs being the main reservoir for this zoonotic infection. Thus, dog infections by L. infantum are needed to develop veterinary drugs and are the best surrogate model for human leishmaniasis. Many contributions on the efficacy of new drugs or presentations in dogs have been published but the variety of experimental designs makes comparisons challenging thus reducing their value. Present study offers a comprehensive review of canine experimental infections with visceral Leishmania, with a particular focus on L. infantum. The review encompasses a range of topics, including animal housing, regulatory aspects, ethical considerations, infection methods, follow-up procedures, and outcomes. The final aim of our contribution is to promote the standardization of some experimental procedures to enhance the comparability of the studies performed. This, in turn, is expected to reduce the use of animals and to increase the efficiency of drug discovery and development
PB Frontiers Media
YR 2026
FD 2026
LK https://hdl.handle.net/20.500.14352/134063
UL https://hdl.handle.net/20.500.14352/134063
LA eng
NO Olías-Molero AI, Corral-Caridad MJ, Jiménez-Antón MD, Mateo-Barrientos M, Carrión J, Torrado JJ and Alunda JM (2026) Standardization of canine infections for the development of antileishmanial drugs. Front. Drug Discov. 6:1754269. doi: 10.3389/fddsv.2026.1754269
NO AO-M: Data curation, Writing – review and editing, Investigation, Methodology, Writing – original draft. MC-C: Writing – original draft, Investigation, Data curation, Writing – review and editing. MJ-A: Data curation, Writing – review and editing, Writing – original draft, Investigation. MM-B: Writing – original draft, Investigation, Writing – review and editing, Data curation. JC: Writing – review and editing, Funding acquisition, Writing – original draft. JJT: Writing – original draft, Writing – review and editing, Methodology. JA: Writing – review and editing, Supervision, Writing – original draft.
NO Ministerio de Cienciaa, Innovación y Universidades (España)
DS Docta Complutense
RD 29 mar 2026